Biogen Idec (Nasdaq: BIIB) said it earned $143 million in the second quarter, or 49 cents a share, down -31% from last year, when the company earned 70 cents a share. The results reflect a $110 million expenditure on Fampridine, a new drug to treat multiple sclerosis. Excluding the purchase,… Read More
Brad Briggs is the Executive Editor of StreetAuthority.com, StreetAuthority Insider. As Executive Editor, Brad manages the team of writers and editors responsible for our two free newsletters, StreetAuthority Daily and Dividend Opportunities as well as all of the free articles on our website, StreetAuthority.com. He is also the managing editor and a regular contributor for StreetAuthority's subscriber-only newsletter, StreetAuthority Insider. Brad joined StreetAuthority in 2008 and has used his journalism training to research and identify opportunities for investors ranging from energy to deep value to momentum plays. Dozens of his articles have been featured on Yahoo Finance, Nasdaq.com and MSN Money, among others. Brad combines his years of experience in the financial industry along with a deep study of behavioral economics and investor psychology to stress the importance of minimizing the role of emotion in trading. Brad is a graduate of Baylor University and has received numerous individual and staff awards from the Society of Professional Journalists, the Texas Intercollegiate Press Association and the Houston Press Club. When not tracking the markets, Brad also enjoys traveling the world.